Axon Dx, LLC, an AXON Connected company, and SRI International, an independent, nonprofit research institute, have entered into an agreement that includes an SRI investment in Axon Dx and a non-exclusive license to certain SRI patents related to cancer diagnostics. Financial details of the agreement were not disclosed.
“The present agreement developed from a collaboration with SRI that began in 2012,” said Kent A. Murphy, Ph.D., president and CEO, Axon Dx. “We are excited to have the support of SRI International and its world-class biosciences research group.”
“We are pleased to announce this new phase of our relationship with Axon Dx,” added Walter H. Moos, Ph.D., vice president of SRI Biosciences. “The next generation of health care products will advance the practice of medicine toward more precise personalized care, including diagnostic tools such as those being developed by Axon Dx.”